| name | endo-pharmaco-eligibility |
| description | Determines if a patient is a candidate for pharmacotherapy based on BMI thresholds: BMI ≥27 kg/m2 with at least one obesity-related comorbidity or BMI ≥30 kg/m2 regardless of comorbidities. Triggered when a clinician asks, “Does this patient qualify for weight‑loss medication based on BMI and comorbidities?” or “Should I consider pharmacotherapy for a patient with BMI 28 and hypertension?”. |
Assess pharmacotherapy eligibility based on BMI/comorbidity
STEP 1 — Gather Information
Collect patient’s current BMI (kg/m2) and screen for obesity‑related comorbidities such as hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea, or cardiovascular disease.
STEP 2 — Rule In / Rule Out
Is the BMI ≥30 kg/m2?
- Yes → Patient meets pharmacotherapy eligibility regardless of comorbidities → proceed to Step 4.
- No → Proceed to Step 3.
STEP 3 — Classify or Stratify
Is the BMI between 27 and <30 kg/m2 and at least one obesity‑related comorbidity present?
- Yes → Patient meets pharmacotherapy eligibility → proceed to Step 4.
- No → Patient does not meet pharmacotherapy eligibility → proceed to Step 4 (negative).
STEP 4 — Decide
If eligible: Recommend initiating pharmacotherapy as an adjunct to comprehensive lifestyle modification, after reviewing drug‑specific contraindications and engaging in shared decision‑making.
If not eligible: Continue lifestyle modification only; reassess eligibility if BMI changes or new comorbidities develop.
Clinical Guardrails / Mimics / Pitfalls
Do not prescribe pharmacotherapy for BMI <27 kg/m2 without comorbidity; avoid in pregnancy or breastfeeding; screen for contraindications (e.g., uncontrolled hypertension, history of heart disease, glaucoma, MAOI use) before prescribing sympathomimetics; ensure shared decision‑making and document discussion of benefits, risks, and alternatives.
Concrete Clinical Example
A 45‑year‑old patient presents with BMI 28 kg/m2 and hypertension. BMI is ≥27 and <30 with a comorbidity (hypertension), so the patient qualifies for pharmacotherapy; lifestyle modification plus a weight‑loss medication is offered after discussing options such as orlistat or a GLP‑1 agonist.
Source: Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2015, DOI:10.1210/jc.2014-3415
